SSI Strategy Holdings LLC, a US-based life science consultancy, is to acquire the NDA Group AB of Sweden in a move that will expand its repertoire of services for pharmaceutical and biotech companies to include regulatory advice as well as support for drug development. The combined group will have a commercial presence across the US and Europe with a capacity to provide services from clinical development to medical affairs and regulation, including the use of real-world evidence to evaluate the effectiveness of new drugs.
The financial terms of the transaction were not disclosed. However it comes nearly three years after SSI received an investment from Amulet Capital Partners LP, a private equity firm, suggesting that the combined group will have sufficient capital to finance growth.
Under the agreement, NDA will operate as a strategic business unit under SSI and be led by the company’s current management team. Johan Strömquist is currently group president and is supported by a team of more than 150 consultants including former regulators and industry experts. NDA has provided services to about a quarter of all new medicinal products approved in the US and Europe over the past three years.
The SSI president, Adam Schwartz, will lead the combined group. He has been with SSI since 2012. In a statement issued on 15 August, Mr Strömquist said that although NDA has provided regulatory services to companies for 25 years, there are still challenges which biotech companies face which are not easy to resolve. “Together with SSI, we can not only optimise the regulatory path, but now also partner with our clients to execute the entire development programme,” he said.
Copyright 2023 Evernow Publishing Ltd.